ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates, has granted stock options to four new employees. The awards, totaling 162,000 common shares, were made on October 1, 2025. The options will vest over four years, with 25% of the shares vesting after one year and the remaining shares vesting in equal monthly installments over the following three years, contingent on continued employment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NY88342) on October 01, 2025, and is solely responsible for the information contained therein.